Researchers advanced next-generation immune cell engineering for solid tumors by reporting in vivo CAR-neutrophils designed for glioma treatment. The work addresses a long-standing technical barrier: directly genetic programming neutrophils in a way that can be translated into therapeutic-grade cells. Separately, LRRK2 substrate biology in Parkinson’s disease continues to produce mechanistic candidates. New findings in npj Parkinson’s Disease point to disruption of the LRRK2–RAB12 interaction as a driver of increased mouse activity, adding to the expanding toolkit of targetable nodes in neurodegenerative pathways. These two developments reflect the field’s dual track—engineering immune effectors for hard-to-treat cancers and identifying actionable signaling vulnerabilities in neurodegeneration.